EUVIMEDEUVIMED entdecken
Crossref

Focused Ultrasound-mediated Disruption of Plasma Protein Binding Enhances Chemotherapeutic Effects of Paclitaxel on Xenografted Ovarian Cancer in Mice

Seung-Schik Yoo, Kathryn Banish, Abduelrahman Fahmi, Carolyn Glasener, Kyungho Yoon, Swati Betharia, Yongzhi Zhang, Kevin Elias, Neil Horowitz

Anticancer Research · 2025

DOI: 10.21873/anticanres.17820 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anticancer Research, 2025. Verfasst von Seung-Schik Yoo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, U.S.A.; yoo@bwh.harvard.edu. Hauptthemen laut MEDLINE: Paclitaxel, Ovarian Neoplasms, Antineoplastic Agents, Phytogenic, Blood Proteins.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND/AIM: Paclitaxel (PTX), a widely-used chemotherapeutic agent, exhibits a high rate of plasma protein binding, which severely limits its bioavailability and reduces therapeutic efficacy. This study explored a novel strategy using low-intensity, non-thermal focused ultrasound (FUS) to locally disrupt PTX-albumin binding, thereby enhancing drug delivery and tumoricidal efficacy at tumor sites without increasing systemic toxicity. MATERIALS AND METHODS: We applied sonication (600 kHz) with varying pulse durations and duty cycles to OVCAR3 cell constructs in vitro and identified the parameters that maximally enhanced PTX uptake and induced tumor cell death. Intracellular PTX concentrations and cell viability were quantified across the conditions. The optimized FUS parameters were then applied to a mouse xenograft model of ovarian cancer using athymic nu/nu mice. Luciferase-expressing OVCAR3 tumor growth was longitudinally monitored using bioluminescence imaging. RESULTS: The sonication parameters (70% duty cycle and 100 ms pulse duration), applied using 3 W/cm2 spatial peak temporal average intensity, optimally enhanced intracellular PTX uptake and increased cell death, independent of thermal or flow-related effects. In vivo, a single FUS treatment nearly doubled intratumoral PTX levels, without altering serum concentration. Repeated FUS sessions combined with PTX treatments over two weeks significantly suppressed tumor growth, compared to no treatment, PTX alone, or FUS alone. Histological analysis in PTX-treated groups showed that FUS did not cause additional damage to the liver, kidney, or surrounding tissues, nor did it affect peripheral blood markers of liver and kidney function. CONCLUSION: FUS can reversibly unbind PTX from albumin, increasing its bioavailability specifically at tumor sites. This targeted approach enhances chemotherapeutic effectiveness without elevating systemic toxicity or causing off-target damage, highlighting FUS as a promising adjuvant strategy for improving anticancer drug delivery in solid tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PaclitaxelOvarian NeoplasmsAntineoplastic Agents, PhytogenicBlood ProteinsAnimalsFemaleHumansMiceXenograft Model Antitumor AssaysCell Line, TumorMice, NudeProtein BindingDrug Delivery SystemsCell SurvivalSonication

Stichwörter der Autor:innen

Low intensity pulsed ultrasoundchemotherapyovarian cancerpaclitaxelplasma protein bindingtherapeutic ultrasound

Substanzen

PaclitaxelAntineoplastic Agents, PhytogenicBlood Proteins

Autor:innen und Institutionen

  • Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, U.S.A.; yoo@bwh.harvard.edu.
  • Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, U.S.A.
  • Department of Biomedical Engineering, Boston University, Boston, MA, U.S.A.
  • School of Mathematics and Computing, Yonsei University, Seoul, Republic of Korea.
  • Department of Pharmaceutical Sciences, Massachusetts College of Pharmacy and Health Sciences, Boston, MA, U.S.A.
  • Department of Obstetrics and Gynecology, Cleveland Clinic, Cleveland, OH, U.S.A.

Zitieren

APA

Yoo, S. S., Banish, K., Fahmi, A., Glasener, C., Yoon, K., Betharia, S., Zhang, Y., Elias, K., & Horowitz, N. (2025). Focused Ultrasound-mediated Disruption of Plasma Protein Binding Enhances Chemotherapeutic Effects of Paclitaxel on Xenografted Ovarian Cancer in Mice. Anticancer Research. https://doi.org/10.21873/anticanres.17820

Vancouver

Yoo SS, Banish K, Fahmi A, Glasener C, Yoon K, Betharia S, et al. Focused Ultrasound-mediated Disruption of Plasma Protein Binding Enhances Chemotherapeutic Effects of Paclitaxel on Xenografted Ovarian Cancer in Mice. Anticancer Research. 2025. doi:10.21873/anticanres.17820

BibTeX
@article{Yoo2025,
  author = {Yoo, Seung-Schik and Banish, Kathryn and Fahmi, Abduelrahman and Glasener, Carolyn and Yoon, Kyungho and Betharia, Swati and Zhang, Yongzhi and Elias, Kevin and Horowitz, Neil},
  title = {Focused Ultrasound-mediated Disruption of Plasma Protein Binding Enhances Chemotherapeutic Effects of Paclitaxel on Xenografted Ovarian Cancer in Mice},
  journal = {Anticancer Research},
  year = {2025},
  doi = {10.21873/anticanres.17820}
}
Kostenlos starten →